Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

NCT04566328 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1450

Enrollment

NETWORK

Sponsor class

Conditions

Plasma Cell Myeloma
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
BIOLOGICAL: Daratumumab and Hyaluronidase-fihj
DRUG: Dexamethasone
DRUG: Lenalidomide
OTHER: Quality-of-Life Assessment

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

National Cancer Institute (NCI)